IP Library Granted Patent US 8,141,417
Granted Patent B2
US 8,141,417 · App. 12/439,184 · Granted Mar 27, 2012

Syringe content detection using RF energy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,141,417
App. No.
12/439,184
Granted
Mar 27, 2012
Kind
B2
Abstract

The present invention includes medical fluid injector systems that detect the contents and/or volume of such contents within a syringe of the system. For example, an RF signal from a first antenna of a medical fluid injector may be transmitted through a syringe associated with the medical fluid injector. At least some of the transmitted RF signal may be received by a second antenna of the medical fluid injector. An amount of the RF signal received by the second antenna may be measured to provide information regarding the contents and/or volume of such contents within the syringe.

Claims (43)

1. A syringe assembly comprising:

a syringe mount; and

a syringe mounted on the syringe mount, the syringe mount comprising:

a source of RF energy;

a first antenna to transmit RF energy from the source, wherein the first antenna is located proximate to the syringe on the syringe mount; and

a second antenna to receive RF energy transmitted from the first antenna, wherein the second antenna is located proximate to the syringe on the syringe mount, and wherein the second antenna is positioned such that at least part of the RF energy that is transmitted from the first antenna travels through the syringe prior to receipt by the second antenna.

2. The syringe assembly of claim 1 , further comprising a third antenna configured to receive RF energy from the first antenna, wherein the third antenna is located proximate to the syringe on the syringe mount, and wherein the third antenna is positioned such that at least part of the RF energy that is transmitted from the first antenna travels through the syringe prior to receipt by the third antenna.

3. The syringe assembly of claim 1 , further comprising an RF receiver, wherein the second antenna is coupled to the RF receiver.

4. The syringe assembly of claim 3 , wherein the RF receiver is configured to measure change in RF energy received by the second antenna from the first antenna.

5. The syringe assembly of claim 1 , wherein the first and second antennae are dipole antennas.

6. The syringe assembly of claim 1 , wherein the first and second antennae are loop antennas.

7. The syringe assembly of claim 1 , wherein the RF energy from the source is adjustable in frequency.

8. The syringe assembly of claim 1 , wherein the RF energy from the source is adjustable in magnitude.

9. The syringe assembly of claim 1 , wherein the RF energy from the source is transmitted at a fixed, predetermined frequency.

10. The syringe assembly of claim 1 , wherein the RF energy from the source is transmitted at a fixed, predetermined magnitude.

11. The syringe assembly of claim 1 , wherein the syringe comprises an RFID tag.

12. A medical injector system comprising the syringe assembly of claim 1 , wherein the medical injector system is configured to compare an amount of the RF energy transmitted from the first antenna with an amount of the RF energy received by the second antenna to determine content within the syringe.

13. A medical injector system comprising the syringe assembly of claim 1 , wherein the medical injector system is configured to compare an amount of the RF energy transmitted from the first antenna with an amount of the RF energy received by the second antenna to determine if medical fluid is present within the syringe.

14. A medical injector system comprising the syringe assembly of claim 1 , wherein the medical injector system is configured to compare an amount of the RF energy transmitted from the first antenna with an amount of the RF energy received by the second antenna to determine an approximate amount of medical fluid in the syringe.

15. A medical injector system comprising the syringe assembly of claim 1 , wherein the medical injector system is configured to compare an amount of the RF energy transmitted from the first antenna with an amount of the RF energy received by the second antenna to determine whether the syringe is filled with: a) medical fluid; b) a mixture of medical fluid and air; or c) air.

16. A method of operation for a medical fluid injector, the method comprising:

transmitting an RF signal from a first antenna of a medical fluid injector through a syringe associated with the medical fluid injector;

receiving at least some of the RF signal via a second antenna of the medical fluid injector; and

measuring an amount of the RF signal received by the second antenna.

17. The method of claim 16 , further comprising:

disabling the medical fluid injector based, at least in part, on the measuring.

18. The method of claim 16 , further comprising:

enabling initiation of an injection protocol based, at least in part, on the measuring.

19. The method of clam 16 , further comprising:

automatically initiating a programmed injection protocol based, at least in part, on the measuring.

20. The method of claim 16 , further comprising:

comparing the amount of the RF signal received by the second antenna to an amount of the RF signal transmitted from the first antenna.

21. The method of claim 16 , further comprising:

determining if medical fluid is present within the syringe, wherein the determining is based, at least in part, on the measuring.

22. The method of claim 16 , further comprising:

determining an approximate volume of medical fluid in the syringe, wherein the determining is based, at least in part, on the measuring.

23. The method of claim 22 , further comprising:

disabling the medical fluid injector if the determined approximate volume is less than that required to perform a programmed injection protocol.

24. The method of claim 22 , further comprising:

providing an audible warning, a visible warning, or a combination thereof if the determined approximate volume is less than that required to perform a programmed injection protocol.

25. The method of claim 16 , wherein the RF signal has a wavelength smaller than a diameter of the syringe.

26. The method of claim 16 , further comprising:

determining whether the syringe is filled with: a) medical fluid; b) a mixture of medical fluid and air; or c) air, all from the measuring.

Assignments (6)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2014
From: MALLINCKRODT LLC
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 034715/0531 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2009
From: GIBSON, CHAD M.; ORTENZI, VERNON D.
To: MALLINCKRODT INC.
Reel/Frame 022321/0191 →